Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for Comorbid Alcohol and Cannabis Dependence
NCT02210195Phase 2Completed
- Sponsor
- Scripps Research
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol dependence and cannabis use disorder (CUD) comparing Aprepitant with Placebo (2 arms). Primary endpoints: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at 8 weeks and Change From Week 0 in Drinking Quantity and Frequency Using Drinks Per Week at 8 weeks. Started Sep 2014; status: completed.
02
Drugs
aprepitant
03
Conditions
alcohol dependencecannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT02210195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210195.